Clinical Studies and Chronic Kidney Disease: What Did we Learn Recently?

Seminars in Nephrology

Volumn 34, Issue 2, 2014, Pages 164-179

  Liabeuf, Sophie ^a,b   Neirynck, Nathalie ^c   Drüeke, Tilman B ^a   Vanholder, Raymond ^c   Massy, Ziad A ^a,d  

^a INSERM   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Chronic kidney disease; Dialysis; Outcomes; RCT; Uremic toxins

Indexed keywords

6 N,N' DIMETHYLARGININE; ALLOPURINOL; AST 120; BETA 2 MICROGLOBULIN; CINACALCET; FEBUXOSTAT; FIBROBLAST GROWTH FACTOR 23; INDICAN; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; P CRESYL SULFATE; PARATHYROID HORMONE; PHOSPHATE; PREBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG; UREMIC TOXIN; URIC ACID; TOXIN;

CHRONIC KIDNEY DISEASE; DIET; END STAGE RENAL DISEASE; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH FLUX DIALYSIS; HUMAN; HYPERURICEMIA; INFLAMMATION; INTERMETHOD COMPARISON; LOW FLUX DIALYSIS; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT DURATION; UREMIA; CLINICAL TRIAL (TOPIC); RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; TREATMENT OUTCOME; UREMIA;

EID: 84899093816     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.02.008     Document Type: Review

References (193)

1. Vanholder R., De Smet R., Glorieux G., Argiles A., Baurmeister U., Brunet P., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003, 63:1934-1943.
2. Duranton F., Cohen G., De Smet R., Rodriguez M., Jankowski J., Vanholder R., et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012, 23:1258-1270.
3. Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Gaziano J.M., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
4. Kestenbaum B., Sampson J.N., Rudser K.D., Patterson D.J., Seliger S.L., Young B., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16:520-528.
5. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
6. Slinin Y., Foley R.N., Collins A.J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005, 16:1788-1793.
7. Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011, 305:1119-1127.
8. Marchais S.J., Metivier F., Guerin A.P., London G.M. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999, 14:2178-2183.
9. Evenepoel P., Rodriguez M., Kettler M. The bone and uremia is it phosphate, parathyroid hormone, FGF-23, KLOTHO or something else?. Semin Nephrol 2014, 34:151-163.
10. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
11. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
12. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Boger S.M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005, 16:2456-2461.
13. Shi B., Ni Z., Zhou W., Yu Z., Gu L., Mou S., et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 2010, 21:444-448.
14. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
15. Aucella F., Maas R., Vigilante M., Tripepi G., Schwedhelm E., Margaglione M., et al. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis 2009, 207:541-545.
16. Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007, 30:1834-1839.
17. Boger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119:1592-1600.
18. Schepers E., Barreto D.V., Liabeuf S., Glorieux G., Eloot S., Barreto F.C., et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:2374-2383.
19. Meinitzer A., Kielstein J.T., Pilz S., Drechsler C., Ritz E., Boehm B.O., et al. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011, 57:112-121.
20. Kiechl S., Lee T., Santer P., Thompson G., Tsimikas S., Egger G., et al. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009, 205:261-265.
21. Schepers E., Speer T., Fliser D., Kielstein J.T. The dimethylarginines ADMA and SDMA and other guanidines: the real water soluble small toxins?. Semin Nephrol 2014, 34:97-105.
22. Niskanen L.K., Laaksonen D.E., Nyyssonen K., Alfthan G., Lakka H.M., Lakka T.A., et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546-1551.
23. Iwashima Y., Horio T., Kamide K., Rakugi H., Ogihara T., Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006, 47:195-202.
24. Chen J.H., Chuang S.Y., Chen H.J., Yeh W.T., Pan W.H. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009, 61:225-232.
25. Kanbay M., Yilmaz M.I., Sonmez A., Solak Y., Saglam M., Cakir E., et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 2012, 36:324-331.
26. Madero M., Sarnak M.J., Wang X., Greene T., Beck G.J., Kusek J.W., et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009, 53:796-803.
27. Feng S., Jiang L., Shi Y., Shen H., Shi X., Jin D., et al. Uric acid levels and all-cause mortality in peritoneal dialysis patients. Kidney Blood Press Res 2013, 37:181-189.
28. Hsu S.P., Pai M.F., Peng Y.S., Chiang C.K., Ho T.I., Hung K.Y. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant 2004, 19:457-462.
29. Suliman M.E., Johnson R.J., Garcia-Lopez E., Qureshi A.R., Molinaei H., Carrero J.J., et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006, 48:761-771.
30. Lee S.M., Lee A.L., Winters T.J., Tam E., Jaleel M., Stenvinkel P., et al. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am J Nephrol 2009, 29:79-85.
31. Latif W., Karaboyas A., Tong L., Winchester J.F., Arrington C.J., Pisoni R.L., et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011, 6:2470-2477.
32. Degoulet P., Legrain M., Reach I., Aime F., Devries C., Rojas P., et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982, 31:103-110.
33. Liu Y., Coresh J., Eustace J.A., Longenecker J.C., Jaar B., Fink N.E., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
34. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739-1742.
35. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
36. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
37. Bhuriya R., Li S., Chen S.C., McCullough P.A., Bakris G.L. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009, 53(Suppl 4):S3-10.
38. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008, 73:1296-1302.
39. Kovesdy C.P., Kalantar-Zadeh K. Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 2008, 40:427-440.
40. Levin A., Djurdjev O., Beaulieu M., Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008, 52:661-671.
41. Schumock G.T., Andress D., Marx S., Sterz R., Joyce A.T., Kalantar-Zadeh K. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Curr Med Res Opin 2008, 24:3037-3048.
42. Kamycheva E., Sundsfjord J., Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004, 11:69-74.
43. Hagstrom E., Hellman P., Larsson T.E., Ingelsson E., Berglund L., Sundstrom J., et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009, 119:2765-2771.
44. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 291:E38-E49.
45. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, 143:3179-3182.
46. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
47. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
48. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009, 24:2792-2796.
49. Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011, 22:956-966.
50. Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
51. Kendrick J., Cheung A.K., Kaufman J.S., Greene T., Roberts W.L., Smits G., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
52. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007, 18:2600-2608.
53. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
54. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
55. Kirkpantur A., Balci M., Gurbuz O.A., Afsar B., Canbakan B., Akdemir R., et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011, 26:1346-1354.
56. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2011, 21:369-375.
57. Neirynck N., Eloot S., Glorieux G., Barreto D.V., Barreto F.C., Liabeuf S., et al. Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS One 2012, 7:e44201.
58. Danesh F., Ho L.T. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial 2001, 14:80-85.
59. Cheung A.K., Rocco M.V., Yan G., Leypoldt J.K., Levin N.W., Greene T., et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006, 17:546-555.
60. Kim K.M., Kim S.S., Kim H., Koo T., Im E.Y., Kim S.B. Higher serum beta2-microglobulin levels are associated with better survival in chronic hemodialysis patients: a reverse epidemiology. Clin Nephrol 2011, 75:458-465.
61. Liabeuf S., Lenglet A., Desjardins L., Neirynck N., Glorieux G., Lemke H.D., et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012, 82:1297-1303.
62. Astor B.C., Muth B., Kaufman D.B., Pirsch J.D., Michael Hofmann R., Djamali A. Serum beta-microglobulin at discharge predicts mortality and graft loss following kidney transplantation. Kidney Int 2013, 84:810-817.
63. Shinkai S., Chaves P.H., Fujiwara Y., Watanabe S., Shibata H., Yoshida H., et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med 2008, 168:200-206.
64. Hoke M., Pernicka E., Niessner A., Goliasch G., Amighi J., Koppensteiner R., et al. Renal function and long-term mortality in patients with asymptomatic carotid atherosclerosis. Thromb Haemost 2012, 107:150-157.
65. Cheung C.L., Lam K.S., Cheung B.M. Serum beta-2 microglobulin predicts mortality in people with diabetes. Eur J Endocrinol 2013, 169:1-7.
66. Foster M.C., Inker L.A., Levey A.S., Selvin E., Eckfeldt J., Juraschek S.P., et al. Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults. Am J Kidney Dis 2013, 62:42-51.
67. Chmielewski M., Cohen G., Wiecek A., Carrero J.J. The peptidic middle molecules: is molecular weight doing the trick?. Semin Nephrol 2014, 34:118-134.
68. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
69. Qureshi A.R., Alvestrand A., Divino-Filho J.C., Gutierrez A., Heimburger O., Lindholm B., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002, 13(Suppl 1):S28-S36.
70. Stenvinkel P., Ketteler M., Johnson R.J., Lindholm B., Pecoits-Filho R., Riella M., et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 2005, 67:1216-1233.
71. Hasuike Y., Nonoguchi H., Ito K., Naka M., Kitamura R., Nanami M., et al. Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol 2009, 30:389-398.
72. Tripepi G., Mallamaci F., Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005, 16(Suppl 1):S83-S88.
73. Rao M., Guo D., Perianayagam M.C., Tighiouart H., Jaber B.L., Pereira B.J., et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005, 45:324-333.
74. Honda H., Qureshi A.R., Heimburger O., Barany P., Wang K., Pecoits-Filho R., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006, 47:139-148.
75. Panichi V., Maggiore U., Taccola D., Migliori M., Rizza G.M., Consani C., et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1154-1160.
76. Pecoits-Filho R., Barany P., Lindholm B., Heimburger O., Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002, 17:1684-1688.
77. Barreto D.V., Barreto F.C., Liabeuf S., Temmar M., Lemke H.D., Tribouilloy C., et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2009, 77:550-556.
78. Dou L., Bertrand E., Cerini C., Faure V., Sampol J., Vanholder R., et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004, 65:442-451.
79. Barreto F.C., Barreto D.V., Liabeuf S., Meert N., Glorieux G., Temmar M., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:1551-1558.
80. Liabeuf S., Barreto D.V., Barreto F.C., Meert N., Glorieux G., Schepers E., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010, 25:1183-1191.
81. Meijers B.K., Claes K., Bammens B., de Loor H., Viaene L., Verbeke K., et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010, 5:1182-1189.
82. Sirich T., Meyer T.W., Gondouin B., Brunet P., Niwa T. Protein-bound molecules: a large family with a bad character. Semin Nephrol 2014, 34:106-117.
83. Yu M., Kim Y.J., Kang D.H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011, 6:30-39.
84. Wu I.W., Hsu K.H., Lee C.C., Sun C.Y., Hsu H.J., Tsai C.J., et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011, 26:938-947.
85. Lin C.J., Liu H.L., Pan C.F., Chuang C.K., Jayakumar T., Wang T.J., et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012, 43:451-456.
86. Melamed M.L., Plantinga L., Shafi T., Parekh R., Meyer T.W., Hostetter T.H., et al. Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. BMC Nephrol 2013, 14:134.
87. Sato B., Yoshikawa D., Ishii H., Suzuki S., Inoue Y., Takeshita K., et al. Relation of plasma indoxyl sulfate levels and estimated glomerular filtration rate to left ventricular diastolic dysfunction. Am J Cardiol 2013, 111:712-716.
88. Sato B., Yoshikawa D., Ishii H., Kikuchi R., Arima T., Takeshita K., et al. Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. Int J Cardiol 2013, 163:214-216.
89. Curtius H.C., Mettler M., Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976, 126:569-580.
90. Meert N., Schepers E., Glorieux G., Van Landschoot M., Goeman J.L., Waterloos M.A., et al. Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrol Dial Transplant 2012, 27:2388-2396.
91. de Loor H., Bammens B., Evenepoel P., De Preter V., Verbeke K. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005, 51:1535-1538.
92. Meijers B.K., Bammens B., De Moor B., Verbeke K., Vanrenterghem Y., Evenepoel P. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008, 73:1174-1180.
93. Lin C.J., Wu C.J., Pan C.F., Chen Y.C., Sun F.J., Chen H.H. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010, 25:3693-3700.
94. Liabeuf S., Glorieux G., Lenglet A., Diouf M., Schepers E., Desjardins L., et al. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins?. PLoS One 2013, 8:e67168.
95. Eloot S., Ledebo I., Ward R.A. Extracorporeal removal of uremic toxins: can we still do better?. Semin Nephrol 2014, 34:209-227.
96. Meert N., Eloot S., Schepers E., Lemke H.D., Dhondt A., Glorieux G., et al. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant 2011, 26:2624-2630.
97. Pedrini L.A., De Cristofaro V., Comelli M., Casino F.G., Prencipe M., Baroni A., et al. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol Dial Transplant 2011, 26:2617-2624.
98. Penne E.L., van der Weerd N.C., van den Dorpel M.A., Grooteman M.P., Levesque R., Nube M.J., et al. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 2010, 55:77-87.
99. Basile C., Libutti P., Di Turo A.L., Casino F.G., Vernaglione L., Tundo S., et al. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis. Nephrol Dial Transplant 2011, 26:1296-1303.
100. Eloot S., Van Biesen W., Dhondt A., Van de Wynkele H., Glorieux G., Verdonck P., et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008, 73:765-770.
101. Evenepoel P., Bammens B., Verbeke K., Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006, 70:794-799.
102. Zhang D.L., Liu J., Liu S., Zhang Y., Liu W.H. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Ren Fail 2010, 32:935-940.
103. Koyama K., Ito A., Yamamoto J., Nishio T., Kajikuri J., Dohi Y., et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis 2010, 55:1069-1078.
104. Kielstein J.T., Fliser D., Veldink H. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?. Sem Dial 2009, 22:346-350.
105. Maduell F., Navarro V., Cruz M.C., Torregrosa E., Garcia D., Simon V., et al. Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis 2002, 40:582-589.
106. Locatelli F., Mastrangelo F., Redaelli B., Ronco C., Marcelli D., La Greca G., et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996, 50:1293-1302.
107. Meert N., Waterloos M.A., Van Landschoot M., Dhondt A., Ledebo I., Glorieux G., et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Org 2010, 34:580-585.
108. Ward R.A., Schmidt B., Hullin J., Hillebrand G.F., Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000, 11:2344-2350.
109. Lindstrom V., Grubb A., Alquist Hegbrant M., Christensson A. Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest 2008, 68:685-691.
110. Haase M., Silvester W., Uchino S., Goldsmith D., Davenport P., Tipping P., et al. A pilot study of high-adsorption hemofiltration in human septic shock. Int J Artif Organs 2007, 30:108-117.
111. Panichi V., Rosati A., Paoletti S., Ferrandello P., Migliori M., Beati S., et al. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif 2011, 32:7-14.
112. Akoglu H., Dede F., Piskinpasa S., Falay M.Y., Odabas A.R. Impact of low- or high-flux haemodialysis and online haemodiafiltration on inflammatory markers and lipid profile in chronic haemodialysis patients. Blood Purif 2013, 35:258-264.
113. Lesaffer G., De Smet R., Lameire N., Dhondt A., Duym P., Vanholder R. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000, 15:50-57.
114. Fagugli R.M., De Smet R., Buoncristiani U., Lameire N., Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002, 40:339-347.
115. Meert N., Eloot S., Waterloos M.A., Van Landschoot M., Dhondt A., Glorieux G., et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009, 24:562-570.
116. Meert N., Beerenhout C., Schepers E., Glorieux G., Kooman J., Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009, 22:352-357.
117. Lin C.L., Huang C.C., Yu C.C., Yang H.Y., Chuang F.R., Yang C.W. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003, 42:524-531.
118. Eloot S., Dhondt A., Van Landschoot M., Waterloos M.A., Vanholder R. Removal of water-soluble and protein-bound solutes with reversed mid-dilution versus post-dilution haemodiafiltration. Nephrol Dial Transplant 2012, 27:3278-3283.
119. Meijers B.K., Weber V., Bammens B., Dehaen W., Verbeke K., Falkenhagen D., et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 2008, 32:214-219.
120. Tijink M.S., Wester M., Glorieux G., Gerritsen K., Sun J., Sousa R., et al. Hollow fiber mixed matrix membranes for removal of protein bound toxins. Biomaterials 2013, 34:7819-7828.
121. Pham N.M., Recht N.S., Hostetter T.H., Meyer T.W. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008, 3:85-90.
122. Vanholder R., Eloot S., Schepers E., Neirynck N., Glorieux G., Massy Z. An obituary for GFR as the main marker for kidney function?. Sem Dial 2012, 25:9-14.
123. Vanholder R., Meert N., Van Biesen W., Meyer T., Hostetter T., Dhondt A., et al. Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?. Nat Clin Pract Nephrol 2009, 5:130-131.
124. Eknoyan G., Beck G.J., Cheung A.K., Daugirdas J.T., Greene T., Kusek J.W., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.
125. Locatelli F., Martin-Malo A., Hannedouche T., Loureiro A., Papadimitriou M., Wizemann V., et al. Membrane Permeability Outcome Study G. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009, 20:645-654.
126. Cheung A.K., Levin N.W., Greene T., Agodoa L., Bailey J., Beck G., et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003, 14:3251-3263.
127. Delmez J.A., Yan G., Bailey J., Beck G.J., Beddhu S., Cheung A.K., et al. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis 2006, 47:131-138.
128. Tattersall J., Canaud B., Heimburger O., Pedrini L., Schneditz D., Van Biesen W., et al. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrol Dial Tansplant 2010, 25:1230-1232.
129. Canaud B., Bragg-Gresham J.L., Marshall M.R., Desmeules S., Gillespie B.W., Depner T., et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006, 69:2087-2093.
130. Panichi V., Rizza G.M., Paoletti S., Bigazzi R., Aloisi M., Barsotti G., et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial 2008, 23:2337-2343.
131. Vilar E., Fry A.C., Wellsted D., Tattersall J.E., Greenwood R.N., Farrington K. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009, 4:1944-1953.
132. Santoro A., Mancini E., Bolzani R., Boggi R., Cagnoli L., Francioso A., et al. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis 2008, 52:507-518.
133. Grooteman M.P., van den Dorpel M.A., Bots M.L., Penne E.L., van der Weerd N.C., Mazairac A.H., et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012, 23:1087-1096.
134. Ok E., Asci G., Toz H., Ok E.S., Kircelli F., Yilmaz M., et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013, 28:192-202.
135. Maduell F., Moreso F., Pons M., Ramos R., Mora-Macia J., Carreras J. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013, 24:487-497.
136. Vanholder R., Eloot S., Neirynck N., Van Biesen W. Home haemodialysis and uraemic toxin removal: does a happy marriage exist?. Nat Rev Nephrol 2012, 8:579-588.
137. Rocco M.V., Lockridge R.S., Beck G.J., Eggers P.W., Gassman J.J., Greene T., et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 2011, 80:1080-1091.
138. Daugirdas J.T., Greene T., Rocco M.V., Kaysen G.A., Depner T.A., Levin N.W., et al. Effect of frequent hemodialysis on residual kidney function. Kidney Int 2013, 83:949-958.
139. Group FHNT, Chertow GM, Levin N.W., Beck G.J., Depner T.A., Eggers P.W., et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010, 363:2287-2300.
140. Sanabria M, Munoz J, Trillos C, Hernandez G, Latorre C, Diaz CS, et al. Dialysis outcomes in Colombia (DOC) study: a comparison of patient survival on peritoneal dialysis vs hemodialysis in Colombia. Kidney Int Suppl. 2008;108:S165-72.
141. Suzuki K., Konta T., Ichikawa K., Ikeda A., Niino H., Hoshikawa M., et al. Comparison of mortality between Japanese peritoneal dialysis and hemodialysis patients: a 5-year multicenter follow-up study. Int J Nephrol 2012, 231018. (2012).
142. Termorshuizen F., Korevaar J.C., Dekker F.W., Van Manen J.G., Boeschoten E.W., Krediet R.T., et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003, 14:2851-2860.
143. Vonesh E.F., Snyder J.J., Foley R.N., Collins A.J. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004, 66:2389-2401.
144. Vonesh E.F., Snyder J.J., Foley R.N., Collins A.J. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?. Kidney Int Suppl 2006, 103:S3-11.
145. Evenepoel P., Meijers B.K. Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. Kidney Int 2011, 81:227-229.
146. Schepers E., Glorieux G., Vanholder R. The gut: the forgotten organ in uremia?. Blood Purif 2010, 29:130-136.
147. Vaziri N.D., Wong J., Pahl M., Piceno Y.M., Yuan J., DeSantis T.Z., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2012, 83:308-315.
148. Meijers B.K., Glorieux G., Poesen R., Bakker S. Non-extracorporeal methods for decreasing uremic solute concentration: a future way to go?. Semin Nephrol 2014, 34:228-243.
149. Uribarri J., Cai W., Peppa M., Goodman S., Ferrucci L., Striker G., et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007, 62:427-433.
150. Capeillere-Blandin C., Gausson V., Nguyen A.T., Descamps-Latscha B., Drueke T., Witko-Sarsat V. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 2006, 21:1555-1563.
151. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., Capeillere-Blandin C., Nguyen A.T., Canteloup S., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
152. Cai W., Gao Q.D., Zhu L., Peppa M., He C., Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002, 8:337-346.
153. Vlassara H., Cai W., Chen X., Serrano E.J., Shobha M.S., Uribarri J., et al. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift. J Gerontol A Biol Sci Med Sci 2012, 67:1410-1416.
154. Sahni N., Gupta K.L., Rana S.V., Prasad R., Bhalla A.K. Intake of antioxidants and their status in chronic kidney disease patients. J Ren Nutr 2012, 22:389-399.
155. Benbernou N., Esnault S., Potron G., Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 1995, 25(Suppl 2):S75-S79.
156. Ferrari P., Mallon D., Trinder D., Olynyk J.K. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) 2010, 15:344-349.
157. Cooper A., Mikhail A., Lethbridge M.W., Kemeny D.M., Macdougall I.C. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004, 15:1877-1882.
158. Nasiri-Toosi Z., Dashti-Khavidaki S., Khalili H., Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 2013, 69:1057-1073.
159. Rossi M., Klein K., Johnson D.W., Campbell K.L. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int J Nephrol 2012, 673631. (2012).
160. Meijers B.K., De Preter V., Verbeke K., Vanrenterghem Y., Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010, 25:219-224.
161. Miyazaki T., Aoyama I., Ise M., Seo H., Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000, 15:1773-1781.
162. Aoyama I., Niwa T. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. Am J Kidney Dis 2001, 37(Suppl 2):S7-S12.
163. Nakagawa N., Hasebe N., Sumitomo K., Fujino T., Fukuzawa J., Hirayama T., et al. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 2006, 26:455-461.
164. Ueda H., Shibahara N., Takagi S., Inoue T., Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007, 11:189-195.
165. Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997, 62:S23-S28.
166. Maeda K., Hamada C., Hayashi T., Shou I., Wakabayashi M., Fukui M., et al. Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J Int Med Res 2009, 37:205-213.
167. Akizawa T., Asano Y., Morita S., Wakita T., Onishi Y., Fukuhara S., et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009, 54:459-467.
168. Ueda H., Shibahara N., Takagi S., Inoue T., Katsuoka Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008, 30:856-860.
169. Nakamura T., Kawagoe Y., Matsuda T., Ueda Y., Shimada N., Ebihara I., et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004, 27:121-126.
170. Nakai K., Fujii H., Kono K., Goto S., Fukagawa M., Nishi S. Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol 2011, 33:218-223.
171. Schulman. EPPIC (evaluating prevention of progression in CKD) results from two phase III, randomized, placebo-controlled, double-blind trials of AST-120 in adults with CKD. American Society of Nephrology Congress 2012, San Diego, California, October 30 - November 4, 2012; Abstract SA_PO1106.
172. Kotegawa T., Tsutsumi K., Morita H., Imai H., Morita M., Yoshizato T., et al. Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans. Eur J Clin Pharmacol 2012, 68:1605-1610.
173. Di Iorio B., Molony D., Bell C., Cucciniello E., Bellizzi V., Russo D., et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013, 62:771-778.
174. Koiwa F., Kazama J.J., Tokumoto A., Onoda N., Kato H., Okada T., et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005, 9:336-339.
175. Oliveira R.B., Cancela A.L., Graciolli F.G., Dos Reis L.M., Draibe S.A., Cuppari L., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5:286-291.
176. Gonzalez-Parra E., Gonzalez-Casaus M.L., Galan A., Martinez-Calero A., Navas V., Rodriguez M., et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011, 26:2567-2571.
177. Yilmaz M.I., Sonmez A., Saglam M., Yaman H., Kilic S., Eyileten T., et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2011, 59:177-185.
178. Isakova T., Gutierrez O.M., Smith K., Epstein M., Keating L.K., Juppner H., et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011, 26:584-591.
179. Block G.A., Wheeler D.C., Persky M.S., Kestenbaum B., Ketteler M., Spiegel D.M., et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012, 23:1407-1415.
180. Drueke T.B., Massy Z.A. Phosphate binders in CKD: bad news or good news?. J Am Soc Nephrol 2012, 23:1277-1280.
181. Chertow G.M., Correa-Rotter R., Block G.A., Drueke T.B., Floege J., Goodman W.G., et al. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant 2012, 27:2872-2879.
182. Chertow G.M., Block G.A., Correa-Rotter R., Drueke T.B., Floege J., Goodman W.G., et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2013, 367:2482-2494.
183. Palmer S.C., Nistor I., Craig J.C., Pellegrini F., Messa P., Tonelli M., et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013, 10:e1001436.
184. Jalal D.I., Chonchol M., Chen W., Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013, 61:134-146.
185. Siu Y.P., Leung K.T., Tong M.K., Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51-59.
186. Goicoechea M., de Vinuesa S.G., Verdalles U., Ruiz-Caro C., Ampuero J., Rincon A., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5:1388-1393.
187. Talaat K.M., el-Sheikh A.R. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007, 27:435-440.
188. Naoyuki K., Shin F., Toshikazu H., Tatsuo H., Kenjiro K., Toshitaka N., et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol 2011, 17(Suppl 2):S44-S49.
189. Schumacher H.R., Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540-1548.
190. Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63.
191. Miao Y., Ottenbros S.A., Laverman G.D., Brenner B.M., Cooper M.E., Parving H.H., et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011, 58:2-7.
192. Ito S., Naritomi H., Ogihara T., Shimada K., Shimamoto K., Tanaka H., et al. Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertens Res 2012, 35:867-873.
193. Locatelli F., Hannedouche T., Jacobson S., La Greca G., Loureiro A., Martin-Malo A., et al. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999, 12:85-88.